Brachytherapy

American Shared Hospital Services Realigns Management Team

Retrieved on: 
Friday, March 10, 2023
AMS, CFO, Brachytherapy, Cardiology, GK, Neuroscience, Interim, Marketing, Executive, American Share Insurance, NYSE, Elekta, Management

SAN FRANCISCO, CA, March 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced several important management changes, all effective as of March 7, 2023.

Key Points: 
  • -Ray Stachowiak Becomes Executive Chairman, Peter Gaccione Appointed CEO-
    SAN FRANCISCO, CA, March 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced several important management changes, all effective as of March 7, 2023.
  • He has served as Chief Executive Officer since October 2020 and previously served as Interim President and Chief Executive Officer from May 2020.
  • Mr. Tagawa served as Chief Operating Officer from 1999-2022, he joined American Shared in 1988.
  • Speaking for myself and the Board of Directors, we have every confidence that our newly aligned management team will lead AMS to new heights,” concluded Mr. Stachowiak.

Global Embolotherapy Market Analysis/Forecasts, 2022-2023 & 2029 - Growing Patient Population With Chronic Conditions Increasing the Demand for Embolization Procedures - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 1, 2023
Health, Other Health, Hospital, Moyamoya disease, TACE, Urology, Microparticle, PVA, Transcatheter arterial chemoembolization, Neurology, TAE, Gelatin, Liver cancer, Arteriovenous malformation, Brachytherapy, Growth, Lung cancer, SIRT, Prevalence, Intracranial aneurysm, AVM, Video game, Speciality chemicals, Pharmaceutical industry, Nursing, Selective internal radiation therapy

The radioembolization segment is expected to grow at high single digit CAGR from 2022 to 2029.

Key Points: 
  • The radioembolization segment is expected to grow at high single digit CAGR from 2022 to 2029.
  • The liquid embolization agents market is expected to grow at early teens CAGR from 2022 to 2029.
  • Factors such as the growing patient population with chronic conditions increasing the demand for embolization procedures, and technology advancements are driving the market growth, whereas, acquisitions and collaborations and emerging markets are providing growth opportunities.
  • The Embolotherapy global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares.

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

Retrieved on: 
Thursday, January 12, 2023
Regulatory T cell, Blood, Prostate cancer, Physician, Columbia University Irving Medical Center, Surgeon, Trial of the century, MDSC, Safety, TAAS, Columbia University Vagelos College of Physicians and Surgeons, MD, PSA, Herbert Irving Comprehensive Cancer Center, NK, Columbia University, Patient, Brachytherapy, Abstract, TME, OTCQX, Herbert, Columbia, Medicine, Prostate-specific antigen, LM, Pharmaceutical industry, Advaxis

MONMOUTH JUNCTION, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced an update on the Phase 1 clinical study evaluating ADXS-504, the company’s off-the-shelf neoantigen drug candidate, in patients with biochemically recurrent (early) prostate cancer that is being conducted at Columbia University Irving Medical Center. Karie Runcie, MD, assistant professor of medicine, and Mark N. Stein, MD, associate professor of medicine, in the division of hematology/oncology at Columbia University Vagelos College of Physicians and Surgeons and members of the Herbert Irving Comprehensive Cancer Center, are the study’s principal and senior investigators, respectively.

Key Points: 
  • The study design of this phase 1 open-label dose escalation study for patients in both dose cohorts was presented at the 2022 ASCO Annual Meeting by Dr. Runcie (Abstract #: TPS5115).
  • The trial is currently expanding enrollment at the second dose level by up to six additional patients for a total of nine patients.
  • “We have completed evaluation of the dose-limiting-toxicity period for three patients at the second dose level for this Phase 1 trial of ADXS-504.
  • We look forward to analyzing the composite data to gain further insight into the safety and efficacy of this novel therapy.”

Worldwide Nasopharyngeal Cancer Industry to 2028 - North America is the Fastest Growing Region - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023
Pharmaceutical, Health, Oncology, EBRT, Hearing loss, Bone, Adenocarcinoma, MRI, Headache, IARC, Megasphaera, Woman, Tobacco, Severe acute respiratory syndrome coronavirus 2, MEA, American Institute, Initial, Squamous cell carcinoma, COVID-19, Organic, Pharynx, News, Immunotherapy, Brachytherapy, Research, Nasopharyngeal carcinoma, Growth, Patient, CT, Chemoradiotherapy, Weight loss, PET, Fatigue, Blurred, Hypoesthesia, Neck, Prevalence, Diagnosis, NPC, Cell, Dietary supplement, Pharmaceutical industry, Medical imaging, Marketing, Cancer

The symptoms of nasopharyngeal cancer include a lump in the neck, hearing loss, stuffiness, numbness, frequent headaches, fatigue, blurred, weight loss etc.

Key Points: 
  • The symptoms of nasopharyngeal cancer include a lump in the neck, hearing loss, stuffiness, numbness, frequent headaches, fatigue, blurred, weight loss etc.
  • According to the American Institute for Cancer Research estimates, Nasopharyngeal cancer is the 23rd most common cancer worldwide, and it is the 18th most commonly occurring cancer in men and the 22nd most commonly occurring cancer in women.
  • Thus, the high prevalence rate of nasopharyngeal cancer will increase the demands for effective drugs and therapies that will further lead to market growth.
  • The global nasopharyngeal cancer market is segmented based on cancer type, diagnosis method, and therapy.

University Hospitals Seidman Cancer Center selects RayStation

Retrieved on: 
Wednesday, January 4, 2023
Photon, Proton therapy, National Cancer Institute, Patient, Case Comprehensive Cancer Center, RaySearch Laboratories, SRS, DRS, Nasdaq Stockholm, SBRT, Health, University Hospitals Cleveland Medical Center, Vincent, Partnership, IMRT, Proton, Safety, Deep learning, Karolinska Institute, Hospital, Carbon, Helium, Workplace, Physics, HDR, Brachytherapy, Ion, TCS, Case, Radiation therapy, OIS, OAS, TPS, Research, Cancer, Electron, Medical imaging, Pharmaceutical industry, Varian, Elekta

STOCKHOLM, Jan. 4, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that University Hospitals Seidman Cancer Center/Case Western Reserve University in Cleveland, Ohio, in the USA, has placed an order in December 2022 and chosen to transition to RayStation®* as its primary treatment planning system.

Key Points: 
  • STOCKHOLM, Jan. 4, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that University Hospitals Seidman Cancer Center/Case Western Reserve University in Cleveland, Ohio, in the USA, has placed an order in December 2022 and chosen to transition to RayStation®* as its primary treatment planning system.
  • University Hospitals Seidman Cancer Center's Department of Radiation Oncology has rapidly transformed into an internationally recognized center of excellence.
  • UH Seidman Cancer Center is part of the Case Comprehensive Cancer Center, one of the nation's leading academic and research institutions.
  • Cancer services are provided by University Hospitals Seidman Cancer Center which is part of the National Cancer Institute-designated Case Comprehensive Cancer Center (the USA's highest designation).

Samsung’s Latest Best-in-Class Technologies Take Center Stage at RSNA 2022

Retrieved on: 
Tuesday, November 22, 2022
Technology, General Health, Health, Artificial Intelligence, Photon, Army Foreign Intelligence Assistance Program, PCD, Communication, LED, Marketing, Patient satisfaction, Night Visions Live, Tablet, Trauma, Senior, Environment, LSI, Multimedia, Memory, Lifting, Brachytherapy, Health, Workflow, ER, AEC, News, Samsung Medison, Booth, Elite, Steven Novella, Radiological Society of North America, Diagnosis, Falls, Dust, V8, Television, Annual general meeting, RSNA, Electronics, Transport, Samsung Electronics, ACCE, VMI, CT, Apple Inc. v. Samsung Electronics Co., Neurosurgery, DQE, Motion, Collimated beam, Artificial intelligence, Google Images, Heart, Patient, Medical imaging, Pharmaceutical industry, Mobile phone, Television set, Samsung

The new on-device AI solution for ultrasound, known as HeartAssist, which can enhance the diagnosis and examination process, will be on display.

Key Points: 
  • The new on-device AI solution for ultrasound, known as HeartAssist, which can enhance the diagnosis and examination process, will be on display.
  • Boston Imaging markets innovative imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers.
  • Boston Imagings growing portfolio of advanced medical technologies is used in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction and increase workflow efficiency.
  • NeuroLogicas growing portfolio of advanced medical technologies are used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction, and increase workflow efficiency.

Latest innovations in RayStation, RayCare and RayIntelligence to be presented at ASTRO 2022

Retrieved on: 
Friday, October 21, 2022
DICOM, Deep learning, Elekta, Efficiency, GE Healthcare, Information system, GE, Canon Medical Systems Corporation, Technology, Solution, IBA, ASTRO, Artemis, CEO, RaySearch Laboratories, Brachytherapy, 6A, Congress, Cyberknife, Medical imaging

STOCKHOLM, Oct. 21, 2022 /PRNewswire/ -- RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ASTRO 2022, to be held in San Antonio, October 23-25.

Key Points: 
  • STOCKHOLM, Oct. 21, 2022 /PRNewswire/ -- RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ASTRO 2022, to be held in San Antonio, October 23-25.
  • Attendees can book demonstrations of RayStation* treatment planning system, RayCare* oncology information system, and RayIntelligence, the cloud-based oncology analytics system, in RaySearch's booth 3785 during the congress.
  • The latest versions of RayStation (12A) RayCare (6A) and RayIntelligence (2A) were released in June 2022.
  • RayStation 12A** brings deep learning segmentation for all users, brachytherapy planning for Elekta afterloaders, as well as numerous enhancements throughout the system, including CyberKnife planning improvements.

Global Brachytherapy Market Report 2022: A $1.03 Billion Market by 2027 - Industry Trends, Share, Size, Growth, Opportunities and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, October 14, 2022
Radiology, Health, Oncology, Gamma, HDR, Disease, Prevalence, Neoplasm, CAGR, Patient, Seed, Brachytherapy, Research, Medical tourism, Cancer, Technology, R, Industry, Awareness, Skin, Radiation, EBT, LDR, COVID-19, Breast, Renewable energy, Animal, Medical imaging, Silver, Sex industry, Potash, Growth

The "Brachytherapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Brachytherapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global brachytherapy market reached a value of US$ 785 Million in 2021.
  • The rising prevalence of different types of cancer is one of the key factors driving the global market.
  • Key Questions Answered in This Report:
    How has the global brachytherapy market performed so far and how will it perform in the coming years?

Promaxo Announces Research Collaboration with the University of Montreal Hospital Research Centre (CRCHUM) for Improved Prostate, Female GYN Cancer Management

Retrieved on: 
Thursday, September 15, 2022
Adult, GYN, Health, Radiation, Gynaecology, Twitter, General Hospital, Canada, CHUM, Prostate, Company, MRI, Fonds, Partnership, CHU, Government, Health Canada, CEO, Technology, Student, Chair, Female, Public health, Doctor of Philosophy, Diagnosis, Robotics, Associate, École Polytechnique, Research, Prostate cancer, GLOBE, University, Jewish General Hospital, AI, Obstetrics, Brachytherapy, Medical imaging, MD, Physics

With this technology, we expect to improve the accuracy of image-guidance for needle navigation and brachytherapy, leading to improved patient outcomes in the future.

Key Points: 
  • With this technology, we expect to improve the accuracy of image-guidance for needle navigation and brachytherapy, leading to improved patient outcomes in the future.
  • With proven expertise in brachytherapy physics and medical imaging development, he will lead a team of students and scientists for this collaboration.
  • The University of Montreal Hospital Research Centre (CRCHUM) is one of North Americas leading hospital research centres.
  • The Company has formed numerous long-term and strategic partnerships with investor groups and corporation as it drives commercialization of the Promaxo MRI system.

Vivos Inc Files a New Patent on the Hydrogel Component of IsoPet®/RadioGel™

Retrieved on: 
Wednesday, September 14, 2022
Half-life, Patent Cooperation Treaty, Temperature, University, Safety, Radiation, Engineering, Human, PCT, Solvent, Sale, FDA, Food, Gel, Sarcoma, Neoplasm, Name, OTCQB, Company, Washington State University Reactor, Private Securities Litigation Reform Act, Confusion, Forward-looking statement, United States patent law, Hydrogel, Brachytherapy, Technology, Quality management system, Patent, Vivos, Tissue, Method, Veterinary medicine, Skin cancer, Injection (medicine), GLOBE, Food and Drug Administration, Marketing, Animal, Structured Product Labeling, FDA Center for Devices and Radiological Health, GMP, 3D printing, Risk management, Medical imaging, Pharmaceutical industry

Over the last eighteen months our team has worked with polymer contracting experts to optimize our hydrogel component.

Key Points: 
  • Over the last eighteen months our team has worked with polymer contracting experts to optimize our hydrogel component.
  • As part of this process, we just filed a patent application on the hydrogel component, while keeping the production refinements as important proprietary intellectual property.
  • This filing was on the heels of another milestone for Vivos, as the US Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, US Patent Application Serial No: 16-459,466.
  • Our new particle patent and our hydrogel component patent filing are significant achievements consistent with our objective for strong intellectual property protection on both of our key components.